Co-Diagnostics, Inc.

CODX

$1.16

+0.00%

N/A+$0.00

Healthcare

Biotechnology

NASDAQ

Active Trading

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the ...

Financial Highlights of CODX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

8.1%

Net Margin

-6523.0%

P/E Ratio

-0.04x

n/a

Debt / Equity

0.14

n/a

Current Ratio

1.81

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

8.1%

Net Margin

-6523.0%

P/E Ratio

-0.04x

Debt / Equity

0.14

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	88.2%	84.0%	38.6%	74.5%	64.3%	—
Operating MarginOperating income as a percentage of revenue.	47.1%	-78.8%	-626.9%	-1023.7%	-5025.5%	—
Net MarginNet income as a percentage of revenue.	37.5%	-41.6%	-518.7%	-961.4%	-7533.6%	—
EBITDA MarginEBITDA divided by revenue.	47.0%	-30.1%	-541.4%	-924.7%	-7615.4%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	46.6%	-55.1%	-559.5%	-959.9%	-7793.2%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	9.14	23.94	10.81	4.41	3.87	—
Quick RatioLiquid assets divided by current liabilities.	8.98	22.57	10.52	4.27	3.59	—
Cash RatioCash and equivalents divided by current liabilities.	7.03	5.93	2.60	0.40	3.36	—
Debt / AssetsDebt as a share of total assets.	0.0%	0.3%	3.1%	3.4%	5.0%	—
Debt / EquityDebt compared with shareholder equity.	0.00	0.00	0.03	0.04	0.06	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	4.68x	6.34x	20.59x	29.53x	3.27x	—
Inventory TurnoverHow often inventory is sold in a year.	5.78x	1.03x	2.51x	0.93x	0.22x	—
Payables TurnoverHow often payables are paid in a year.	19.05x	5.76x	2.82x	0.30x	0.12x	—
Asset TurnoverRevenue generated per dollar of assets.	0.61x	0.28x	0.07x	0.06x	0.03x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	1.17x	0.36x	0.09x	0.10x	0.04x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	7.03x	-5.57x	-1.11x	-0.60x	-0.14x	—
P/B RatioPrice paid for each dollar of book value.	1.92x	0.69x	0.45x	0.42x	0.33x	—
P/S RatioPrice paid for each dollar of sales.	2.63x	2.32x	5.73x	5.81x	10.83x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	6.38x	15.43x	-1.66x	-0.76x	-0.23x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Supply Chain of CODX

RELATIONS

Upstream

Bio Molecular Systems (BMS)Merck KGaA (MilliporeSigma / Sigma-Aldrich)ETR:MRKThermo Fisher Scientific Inc.NYSE:TMOSynbiotics LtdAmbalal Sarabhai Enterprises Ltd (ASE)BSE:500009

Downstream

CoSara Diagnostics Pvt Ltd (India JV)CoMira Diagnostics (Saudi Arabia JV)Mexico Distributor (Longstanding Partner)American Bio Medica Corporation (ABMC)OTCPINK:ABMCAimil Ltd

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer